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Vaccines  consisting  of  subunit  or  inactivated  bacteria/virus  and potent  adjuvants  are  widely  used  to
control  and  prevent  infectious  diseases.  Because  inactivated  and  subunit  antigens  are  often  less  antigenic
than  live  microbes,  a growing  need  exists  for the  development  of  new  and  improved  vaccine  adjuvants
that  can  elicit  rapid  and  long-lasting  immunity.  Here  we  describe  the  development  and  characterization  of
a  novel  oil-in-water  emulsion,  OW-14.  OW-14  contains  low-cost  plant-based  emulsiﬁers  and  was  added
to antigen  at  a ratio  of  1:3 with  simple  hand  mixing.  OW-14  was  stable  for prolonged  periods  of  time at
temperatures  ranging  from  4  to 40 ◦C and  could  be  sterilized  by autoclaving.  Our results  showed  that  OW-
14  adjuvanted  inactivated  swine  inﬂuenza  viruses  (SIV; H3N2  and  H1N1)  and  Mycoplasma  hyopneumoniae
(M.  hyo)  vaccines  could  be  safely  administered  to  piglets  in  two  doses,  three  weeks  apart.  Injection  sites
were  monitored  and  no  adverse  reactions  were  observed.  Vaccinated  pigs  developed  high  and  prolongedaccine antibody  titers  to  both  SIV  and  M.  hyo.  Interestingly,  antibody  titers  were  either  comparable  or  greater
than  those  produced  by commercially  available  FluSure  (SIV)  or RespiSure  (M.  hyo)  vaccines.  We  also
found  that  OW-14  can  induce  high  antibody  responses  in  pigs  that were  vaccinated  with  a decreased
antigen  dose.  This  study  provides  direct  evidence  that  we  have  developed  an  easy-to-use  and  low-cost
emulsion  that  can  act as  a powerful  adjuvant  in  two  common  types of swine  vaccines.
©  2015  The  Authors.  Published  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).. Introduction
Although attenuated live organisms are frequently used as
accines to control infectious diseases, these modiﬁed live vac-
ines (MLV) may  pose potential safety risks when administered
o immune-compromised animals or the virus/bacteria is capa-
le of reverting to a virulent form. Another disadvantage of using
odiﬁed live vaccines in disease management is that it is difﬁ-
ult to differentiate infected from vaccinated animals. Inactivated
irus/bacteria, puriﬁed proteins, and synthetic peptides are con-
idered to be much safer compared to live pathogens, but they
re often less immunogenic [1,2]. Consequently, these vaccines
∗ Corresponding author. Tel.: +1 785 532 4506; fax: +1 785 532 4557.
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/).rely on adjuvants to stimulate the innate immune response which
in turn facilitates a strong adaptive response [3]. The incorpo-
ration of an adjuvant into a vaccine can achieve qualitative and
quantitative alteration of the immune protection and provide func-
tionally appropriate types of immune responses. Adjuvants also
act to reduce the antigen dose required to generate a protective
response and extend the duration of effective immunity [4]. New
vaccine candidates have been developed recently against not only
infectious agents but also allergic and autoimmune diseases, can-
cer, and infertility [5–10]. All these applications require adjuvants
with desirable functions and performance in order to successfully
achieve vaccination-induced immune protection and therapeutic
effects.Adjuvants can be broadly divided into two  categories, the ﬁrst
being antigen vehicles, such as emulsions and liposomes, which
act to present vaccine antigens to the immune system in a more
efﬁcient way and prolong the release of antigens to increase the
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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peciﬁc immune responses [11]. The second category of adjuvants
re immuno-stimulants, such as Toll-like receptor (TLR) agonists,
luminum hydroxide, saponins and cytokines [12,13]. One major
imiting factor of adjuvants is that many of them have unaccept-
ble side effects and lack of biocompatibility. The most commonly
sed adjuvant in the U.S. is aluminum hydroxide (ALOH). ALOH
s considered safe and is currently a component of several veteri-
ary and human vaccines [14]. However, recent reports suggest
hat ALOH adjuvants lack efﬁcacy for several pathogens [15]. Con-
entional oil-in-water emulsions use various chemical emulsiﬁers
i.e. Tween 80 and Span 80), but the safety of these chemicals
hen injected intramuscularly remains controversial [16]. Here,
e use food-grade plant-derived surfactants commonly used in
uman food processing as emulsiﬁers to stabilize a novel oil-in-
ater emulsion, referred to as OW-14. OW-14 uses inexpensive,
eadily available materials, is stable at temperatures up to 40 ◦C,
nd can be autoclaved for sterilization. Furthermore, OW-14, when
ixed with whole inactivated swine inﬂuenza and mycoplasma
ntigens can elicit higher and prolonged antibody responses than
ommercial vaccines for the same pathogens. Here, we provide evi-
ence that OW-14 emulsion is a low-cost, easy-to-use alternative
djuvant for use in swine vaccines.
. Materials and methods
.1. Materials
Whole killed swine inﬂuenza virus (H3N2, 1.6 mg/ml) and whole
illed Mycoplasma hyopneumoniae (M.  hyo) bacterin (20 mg/ml)
ere purchased from Newport Labs (Worthington, MN). Commer-
ial SIV antigen from FluSure® (H1N1 and H3N2) without adjuvant,
luSure® vaccine, and RespiSure® (M.  hyo) vaccines were pur-
hased from Zoetis (Florham Park, NJ). Ticamulsion A-2010 was
urchased from Tic Gums (White Marsh, MD). Penreco Drakeol 5
il was purchased from Penreco (Karns City, PA).
.2. Emulsion and vaccine formulation
To make the OW-14 emulsion adjuvant, Ticamulsion A-2010,
 Gum arabic emulsiﬁer was dissolved in deionized water with
 7.5% (W/V) ﬁnal concentration. Mineral oil (Penreco Drakeol 5)
as added to the water phase (15%, w/v) and mixed on a Silverson
ab mixer (L5M-A, Silverson, East Longmeadow, MA) for 15 min
t 10,000 rpm. The emulsion was then passed ﬁve times through a
icroﬂuidizer (M-110P, Microﬂuidics, Newton, MA)  at ∼10,000 psi.
mulsions were sterilized by autoclaving for 20 min  at 117 ◦C and
tored at 4 ◦C, room temperature, or 40 ◦C. Vaccines were prepared
y simple hand mixing OW-14 with antigens to produce a ﬁnal
% w/v of mineral oil and 2.5% w/v of the Ticamulsion A-2010.
he viscosity of OW-14 was measured using a Barnant falling ball
iscometer (Fisher Sci., Waltham, MA).
.3. Transmission electron microscopy
OW-14 emulsion was visualized used a Transmission Election
icroscope housed within the Department of Biology at Kansas
tate University. Undiluted OW-14 was placed on a 200 mesh
ormvar-carbon ﬁlter (Electron Microscopy Sciences, Hatﬁeld, PA)
or 5 min  at room temperature. Samples were then counterstained
ith uranyl acetate for 5 min  at room temperature. Grids were air-
ried and imaged on FEI CM100 Transmission Electron Microscope
TEM) equipped with an AMT  digital image capturing system using
 magniﬁcation of 130,000 and an accelerating voltage of 100 kV.ne 33 (2015) 2903–2908
2.4. Particle size and zeta potential characterization
Adjuvants were diluted in deionized water before being ana-
lyzed on a Malvern Zetasizer Nano ZS 90 instrument (Malvern
Instruments, Westborough, MA). The particle size distribution was
measured by dynamic light scattering (DLS), where the distribution
of diffusion coefﬁcients was  determined through the measurement
and correlation of the statistical ﬂuctuations in the light scattered
from a system of particle diffusion under the inﬂuence of Brown-
ian motion. Adjuvants were then assayed for zeta potential using
automatic software determination. Measurements were taken in
triplicate to assess repeatability of the results and highlight any
sample changes such as agglomeration or sedimentation during
measurements.
2.5. Swine vaccination experiments
All animal experiments were approved by the Institutional
Animal Care and Use Committee at Kansas State University. Con-
ventional large White-Duroc crossbred weaned speciﬁc-pathogen
free piglets (3 weeks of age) were used in all studies. The
adjuvant/vaccine efﬁcacy evaluation and adjuvant thermal stabil-
ity/efﬁcacy studies were conducted at the Swine Research Unit,
Kansas State University. The antigen sparing experiment was con-
ducted at Large Animal Research Center (LARC) facility, Kansas State
University. All piglets were conﬁrmed sera-negative for antibod-
ies to swine inﬂuenza virus (by hemagglutination inhibition test)
and M. hyo on day 0. For each experiment, pigs were immunized
intramuscularly using a 20 gauge needle on day post-vaccination
(DPV) 0 and 21 with experimental or commercial vaccines. During
the adjuvant/vaccine efﬁcacy evaluation experiment, blood sam-
ples were collected on day 0, 3 weeks, 5 weeks, 2 months, 4 months,
and 5 months post initial vaccination. During adjuvant thermal sta-
bility/efﬁcacy studies, blood samples were collected on DPV  0, 21,
and 35. During the antigen sparing experiment blood samples were
collected at DPV 0 and 42. Serum was separated from clotted blood
and preserved at −20 ◦C. Vaccine injection sites were examined by
trained veterinary pathologists on the day of slaughter (5 months
post initial vaccination) for any pathological changes to the muscle
or surrounding tissues. Pigs vaccinated with experimental adju-
vant/vaccines were slaughtered/euthanized and disposed at the
end of the experiments.
2.6. Antibody response
Serum was  sent to Iowa State University Veterinary Diagnostic
Laboratory (Ames, IA) for the evaluation of M. hyo antibody produc-
tion using IDEXX M. hyo. Ab Test (IDEXX Laboratories, Westbrook,
ME)  according to their standard protocols.
2.7. Hemagglutination inhibition titer
The hemagglutination inhibition (HAI) test is the most accurate
serologic method of determining a swine herd’s immune status
[17]. Serum was  heat inactivated for 30 min  at 56 ◦C then diluted 10
fold and incubated with chicken red blood cells (RBC’s) overnight
at 4 ◦C. Samples were serially diluted (1:2), mixed with 4 HA units
(HAU) of whole killed H3N2 swine inﬂuenza virus, and incubated
for 30 min  at room temperature. Chicken RBC’s (0.5%) were added
to the samples and incubated 3 h at room temperature. The HAI titer
was deﬁned as the highest serum dilution that completely inhibited
hemagglutination.
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Fig. 1. Oil-in-water emulsion (OW-14) formulated with a cost-effective edible plant derived emulsiﬁer is highly stable at room temperature and 4 ◦C. A plant-based emulsiﬁer
was  dissolved in water before adding oil and mixed for 15 min  at 10,000 rpm. Emulsion was  then passed ﬁve times through a microﬂuidizer and sterilized by autoclaving.
Vaccines were prepared by simple hand mixing OW-14 with antigens to produce a ﬁnal 5% w/v  of oil. (A) Oil droplets were visualized by Transmission Electron Microscopy
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.8. Statistical analysis
Data from pig experiments are the mean ± SEM values from
roups of ﬁve or six pigs. The differences among each treat-
ent group were determined by the one-way analysis of variance
ANOVA) followed by post-hoc Tukey’s test using GraphPad Prism
 software (San Diego, CA).
. Results
.1. Creation of a stable oil-in-water emulsion (OW-14) using a
lant-based, food-grade emulsiﬁer.
The OW-14 emulsion was made in two steps. First, 7.5% Tica-
ulsion A-2010 powder was made with deionized water in a high
peed mixer. After the Ticamulsion A-2010 was  dissolved in water,
5% w/v of mineral oil was added and mixed at 10,000 RPM for
0 min. Secondly, the above oil–water mixture was  then passed
hrough a microﬂuidizer ﬁve times at a pressure of ∼10,000 PSI.
he resulting milky like emulsion was named OW-14. OW-14 was
terilized by autoclaving using a 20 min  liquid cycle. The density
f OW-14 was 1.01 and viscosity was 13.61 cP. Emulsions were
maged under an electron microscope and Fig. 1A shows that OW-
4 formed oil droplets over a range of sizes. Therefore, a particle
nalyzer was used to determine the average size of the emulsiﬁed
il droplets. OW-14 emulsions were stored at room temperature or
◦C for 3 days, 3 months, or 3 years. Oil droplets were uniform and
ono-dispersed and between 100 and 700 nm in diameter (Fig. 1B).
n freshly made OW-14, the average hydrodynamic diameter of the
il droplets was 236 ± 1.6 nm (Mean ± SD, Fig. 1C). The average oil
roplet size did not signiﬁcantly change with time, temperatures, or
utoclaving, indicating that the oil droplets were stable. Emulsion
roplets had an average zeta potential of less than −40 V (Fig. 1D),ern Zetasizer Nano ZS 90 instrument. The particle size distribution was measured
r zeta potential using automatic software determination. All measurements were
which also suggests that OW-14 is a highly stable oil-in-water
emulsion.
3.2. OW-14 emulsion acts as a potent adjuvant for swine
inﬂuenza and M.  hyo antigens and promotes prolonged antibody
responses in pigs
To assess the adjuvanticity of our OW-14 emulsion formulation,
we mixed it with killed H3N2 and H1N1 swine inﬂuenza virus (from
FluSure) and killed M. hyo. One part OW-14 was added to two parts
antigen and the tubes were inverted three times to mix. The anti-
gen/adjuvant mixture was  stable for greater than 3 months when
stored at 40 ◦C, greater than 6 months when stored at 25 ◦C, and
over 1 year when stored at 4 ◦C (data not shown). OW-14/antigen
formulation or commercial vaccines FluSure (positive control for
SIV vaccination) and RespiSure (positive control for M.  hyo vacci-
nation) were intramuscularly administered into pigs twice at an
interval of 3 weeks. OW-14 formulations as well as commercial
vaccines were easily administered to pigs with a standard 5 cm3
syringe coupled to a 20 ga needle. In order to track the antibody
response induced by the vaccines, blood samples were collected
and serum was  isolated throughout the study until the pigs reached
to market age and were slaughtered. Analysis of antigen-speciﬁc
serum IgG revealed that 35 days post vaccination, pigs vaccinated
with OW-14-based vaccines and pigs vaccinated with commercial
vaccines both developed high HAI titer to H3N2 (Fig. 2A) and high
titers of M.  hyo-speciﬁc antibodies (Fig. 2B). Furthermore, H3N2 and
M. hyo-speciﬁc antibody titers remained high in pigs administered
with OW-14 formulated vaccines until market age (ﬁve months
post vaccination) while titers in pigs receiving RespiSure or FluSure
vaccines dropped by four months post vaccination.
The injection sites of all animals were monitored weekly
throughout the study. Pigs vaccinated with FluSure, RespiSure, and
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Fig. 2. OW-14 adjuvanted vaccines induce long lasting and high level antibody
response against swine inﬂuenza virus and mycoplasma antigens in pigs. Pigs (3
weeks old, 5 pigs/group) were vaccinated on Day 0 & 21 with swine inﬂuenza
virus and Mycoplasma hyopneumoniae antigens mixed with or without adjuvant.
The  antibody response was  followed until pigs reached to market age (5 months).
Pathology evaluation at necropsy (5 months) did not ﬁnd any injection site damage
in  any animals. (A) Hemagglutination inhibition titers against whole killed H3N2
swine inﬂuenza virus. The threshold for seroconversion was set at 320, which was 2
fold over negative pig serum. (B) Mycoplasma hyopneumoniae antibody production
using IDEXX M.  hyo. Ab kit. The threshold for seroconversion was  set at a sample-to-
positive (s/p) ratio of 0.4 according to manufacturers’ instructions. (−): unvaccinated
pigs (negative control); Ag only: pigs administered with antigens only; Adj only: pigs
administered with adjuvant OW-14 only; OW-14: pigs administered with vaccines
adjuvanted with OW-14; RespiSure and FluSure: Pigs vaccinated with commercial
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Fig. 3. OW-14 exposed to high temperatures is still an effective adjuvant for swine
inﬂuenza virus (SIV) and mycoplasma vaccines. OW-14 adjuvant was stored at 4 ◦C,
room temperature (RT), or 40 ◦C for 2 weeks prior to be being mixed with SIV and
M.  hyo antigens. Pigs (3 weeks old, 6 pigs/group) were vaccinated on Day 0 & 21. (A)
Hemagglutination inhibition titers against whole killed H3N2 swine inﬂuenza virus.
The threshold for seroconversion was set at 320, which was 2 fold over negative pig
available FluSure and RespiSure vaccines due to their proven ability
to induce high antibody responses and protection against microbialaccines RespiSure and FluSure, respectively. * p < 0.05.
W-14/antigen had small (<2 cm)  lumps in the neck muscle 1 week
ost vaccination. The lumps were not inﬂamed or readily visible
nd resolved by 2 weeks post injection. At slaughter, injection sites
nd all surrounding tissues were blindly examined by a veterinary
athologist. None of the animals had pathological changes to the
issue (data not shown).
.3. OW-14 exposed to high temperatures is still an effective
djuvant for swine inﬂuenza and mycoplasma vaccines
Due to limited cold-chain availability at most farms, an ideal
wine vaccine would not require refrigeration and could be sub-
ected to transient warm environments. In order to determine if
ur OW-14 formulation was stable at transient high temperature,
W-14 was prepared as described above. OW-14 was  then stored
t 4 ◦C, room temperature (RT), or 40 ◦C for two weeks prior to
eing mixed with SIV and M.  hyo antigens. OW-14 formulated or
ommercial vaccines were administered to pigs via intramuscular
njection twice, three weeks between doses. Blood samples were
ollected and serum was isolated to monitor the development of
ntigen-speciﬁc IgG antibodies. It was found that HAI titers to H3N2
ntigens were higher in OW-14 formulated vaccines than commer-
ial FluSure vaccines at 35 days post vaccination (Fig. 3A). Fig. 3B
hows that all OW-14 formulated vaccines, regardless of storage
emperature, elicited an M.  hyo antibody response greater than
ommercially available RespiSure vaccine 35 days post vaccination.serum. (B) Mycoplasma hyopneumoniae antibody production using IDEXX M.  hyo. Ab
kit. The threshold for seroconversion was set at a sample-to-positive (s/p) ratio of
0.4  according to manufacturers’ instructions. * p < 0.05.
3.4. OW-14 adjuvant induces robust antibody production even at
lower antigen doses
We  mixed the OW-14 adjuvant with the standard antigen dose
(1 mg  H3N2 and 13.34 mg  M. hyo), or diluted the antigens with PBS
to create a vaccine containing a 50% antigen dose (0.5 mg  H3N2 and
6.67 mg  M. hyo), or 25% antigen dose (0.25 mg H3N2 and 3.34 mg
M. hyo). Pigs were vaccinated with one of the three vaccines for-
mulations on day 0 and 21 of the study. On day 42, serum was
collected and assayed for H3N2- and M. hyo-speciﬁc antibodies.
Pigs immunized with the 50% antigen dose had similar levels of
antigen-speciﬁc antibody titers as that in pigs vaccinated with the
full dose antigens (Fig. 4).
4. Discussion
One type of the cost-effective vaccine adjuvants is oil-in-water
emulsions and they have been used in animal vaccines for over 50
years. We  show here the development and characterization of a
novel oil-in-water adjuvant formulation using a modiﬁed starch-
based plant emulsiﬁer (Ticamulsion A-2010). This emulsion is made
with food-grade emulsiﬁer and therefore could alleviate safety
concerns with current detergent-emulsiﬁed formulations [16]. We
have demonstrated that this formulation, OW-14, is stable for up
to 3 years when stored at <25 ◦C (Fig. 1) and oil droplets were
determined to be between 50 and 700 nm with an average diam-
eter of 240 nm,  which has been determined to be the optimal size
for stimulating the immune system [18–20]. Furthermore, OW-14
was stable, had a long shelf-life, and could easily be sterilized by
autoclaving (Fig. 1).
We compared OW-14 formulated vaccines to commerciallychallenges [21–23]. Our results show that vaccines adjuvanted with
OW-14 induce antibody responses equal to or better than that from
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Fig. 4. OW-14 adjuvant induces robust antibody production even at lower antigen doses. OW-14 adjuvant was  mixed with SIV and M.  hyo. antigens. 100% antigen was equal
to  1 mg  of whole inactivated H3N2 virus and 13.34 mg  of whole inactivated M. hyo. Pigs (3 weeks old, 5 pigs/group) were vaccinated on Day 0 & 21. (A) Hemagglutination
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[nhibition titers against whole killed H3N2 swine inﬂuenza virus. The threshold for 
yopneumoniae antibody production using IDEXX M. hyo. Ab kit. The threshold for se
nstructions. * p < 0.05.
ommercial products (Figs. 2 and 3). In light of the fact that high
ntibody titers do not always correlate with protection, a future
tudy in which vaccinated pigs are challenged with swine inﬂuenza
irus or M.  hyo will be essential in order to determine the efﬁcacy
f vaccines adjuvanted with OW-14.
The HI titers in pigs vaccinated with OW-14-experimental vac-
ine or the commercial vaccine at ﬁve weeks and two  months post
accination were signiﬁcantly higher than that in control pigs (pigs
dministered with PBS, antigen alone, or adjuvant alone). How-
ver, a HI titer of ∼300 in these control pigs at two  months after
he experiment started indicates that there might be a subclini-
al SIV infection in the herd. Furthermore, although the antibody
esponses in pigs vaccinated with OW-14-adjuvanted mycoplasma
accine were comparable among different studies, we did observe
 discrepancy on the anti-mycoplasma antibody titers in pigs vacci-
ated with RespiSure at ﬁve weeks post vaccination between two
ifferent experiments: ∼1.5 in Fig. 2B and ∼ 0.5 in Fig. 3B. There
as no difference in the amount of RespiSure antigen or adjuvant
sed for the work reported in Figs. 2B and 3B. The difference in anti-
ycoplasma antibody titer between the two experiments could be
ue to the variation of pigs used in these two studies or the product
ot difference of RespiSure which was obtained from a commercial
ource on two different dates.
Mineral oil such as Penreco Drakeol 5 is routinely used to make
il-in-water emulsion adjuvants for animal vaccines. The use of
icamulsion A-2010, a food grade plant-based emulsiﬁer and a sim-
le mixing protocol allow us to produce OW-14 at only a fraction of
 penny per dose of vaccine. Additionally, we show in Fig. 4 that pigs
accinated with vaccines containing half or a quarter of the amount
f antigen produced high antibody titers at 42 days post vacci-
ation. These results suggest that the amount of antigen within
W-14-formulated vaccines can be reduced and the vaccine will
till be efﬁcacious. Therefore, lowering the amount of antigen will
urther cut the overall cost of administering SIV and/or mycoplasma
accines in pigs.
. Conclusion
We  have created a stable oil-in-water emulsion (OW-14) using
ost-effective emulsiﬁers and oils. Animals vaccinated with OW-
4-formulated vaccines had high antigen-speciﬁc antibodies titers,
hich were higher and lasted longer than that in pigs administered
ith commercial vaccines. We  also found that vaccines formulated
ith lower antigen doses also produced a high antibody response.
herefore, OW-14 could be a cheaper and more effective alternate
djuvant for use in animal vaccines.
[nversion was set at 320, which was 2 fold over negative pig serum. (B) Mycoplasma
version was set at a sample-to-positive (s/p) ratio of 0.4 according to manufacturers’
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